Serial PET scans demonstrate the success and limitations of antiangiogenic treatment in a case of lung adenocarcinoma

Clinical Nuclear Medicine

Volumn 33, Issue 9, 2008, Pages 635-637

  Zhu, Zhaohui ^a   Li, Fang ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Antiangiogenic therapy; Bevacizumab; Erlotinib; F 18 FDG PET; Non small cell lung cancer; Serial PET follow up

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; OXALIPLATIN; PEMETREXED; ANGIOGENESIS INHIBITOR;

ADULT; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER SIZE; CASE REPORT; FOLLOW UP; HUMAN; LIVER SCINTISCANNING; LUNG ADENOCARCINOMA; LUNG RESECTION; MALE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; RADIOISOTOPE DISTRIBUTION; TREATMENT RESPONSE; ADENOCARCINOMA; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; SCINTISCANNING; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS; TREATMENT OUTCOME;

EID: 55449133377     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3181813116     Document Type: Article

References (8)

1. Giaccone G. The potentials of antiangiogenic therapy in non-small cell lung cancer. Clin Cancer Res. 2007;13:1961-1970.
2. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: Prognostic and therapeutic implications. J Clin Oncol. 2005;23:3243-3256.
3. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355: 2542-2550.
4. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevaci-zumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23:2544-2555.
5. Sandler A, Herbst R. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res. 2006;12(14 Pt 2):4421s-4425s.
6. Goshen E, Davidson T, Zwas ST, et al. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan. Technol Cancer Res Treat. 2006;5:37-43.
7. Willett CG, Duda DG, di Tomaso E, et al. Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat Clin Pract Oncol. 2007;4:316-321.
8. Goessl C, Grozdanovic Z. PET concerns in bevacizumab treatment. Nat Med. 2004;10:561.